ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2787

−21 HLA-Class I Dimorphism Differentiates Psoriatic Arthritis (PsA) from Psoriasis without Psoriatic Arthritis (PsC)

Vinod Chandran1, Quan Li2, Rohan Machhar2, Fatima Abji1, Justine Y. Ye1, Rajan Nair3, Philip Stuart3, Katerina Oikonomopoulou2, James T. Elder4, Dafna D Gladman2 and Proton Rahman5, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3University of Michigan, Ann Arbor, MI, 4University of Michigan Medical School, Ann Arbor, MI, 5Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: genetics, human leukocyte antigens (HLA), natural killer (NK) cells, pathogenesis and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: 5T046 ACR Abstract: Plenary Session III (2785–2790)

Session Type: ACR Plenary Session

Session Time: 11:00AM-12:30PM

Background/Purpose: The association between human leukocyte antigen (HLA) class I alleles and psoriatic disease indicates a potential role for the innate immune system in disease pathogenesis. HLA class I educates NK cells through interactions with killer cell Immunoglobulin receptors (KIRs) and by supplying peptides that bind HLA-E to form ligands for the more conserved CD94/NKG2A NK receptors. The peptides corresponding to residues −22 to −14 of the leader sequence of HLA-A, HLA-B, and HLA-C specifically bind to the binding site of HLA-E. In ~80% of HLA-B allotypes, methionine at position −21M (21M) is replaced by threonine. Methionine −21 delivers functional peptides, whereas threonine at this position (−21T) does not. This functional dimorphism divides the human population into three groups: −21M/M, M/T, and T/T, with decreased order of potency of the NK CD94/NKG2A+ receptor. We aimed to determine whether the distribution of the M and T haplotypes differed between patients with PsA, PsC and healthy controls.

Methods: Two sets of cohorts were included in this study: (a) A discovery cohort of 664 PsA patients, 1155 PsC patients and 3118 controls. Class I HLA alleles were imputed using SNP2HLA. Logistic regressions were used to obtain the association p values by PLINK. We performed three association analyses between HLA B -21 amino acid polymorphisms and different phenotypes: 1) PsC vs. controls; 2) PsA vs. controls; 3) PsA vs. PsC. Population stratification and sex were controlled by including the top seven principal components and sex as covariates in logistic regression. (b) A replication cohort of 1177 PsA patients, 659 PsC patients and 1096 controls with self reported European ethnicity from a large well-phenotyped single centre cohort. HLA typing was done by sequence specific oligonucleotide (SSO) probes using the reverse line blot technique with ambiguous results resolved using sequence specific primers (PCR-SSP). Association analyses as with the Discovery cohort were repeated. All analyses were conditioned on HLA-B*27.

Results:

PsC patients within our discovery cohort had a significantly lower prevalence of -21M compared to controls as well as those with PsA (Table 1). The results of the replication study showed similar results (Table 2).

Conclusion: The study provides indications for a potential role of NK cells in PsA pathogenesis, as well as provides a genetic marker that differentiates PsA from PsC.

Table 1. Results of the association study in the discovery cohort.

Comparisons

Freq of -21M in affected

Freq -21M in controls

OR (95% CI)

P value

P value

(adjusted)

PsC vs. Controls

0.285

0.331

0.78 (0.70, 0.87)

4.262e-05

4.411e-06

PsA vs. Controls

0.337

0.331

1.04 (0.92, 1.18)

0.671

0.546

PsA vs. PsC

0.337

0.285

1.36 (1.17, 1.58)

0.001

6.692e-05

Table 2. Results of the association study in the replication cohort.

Comparisons

Freq of -21M in affected

Freq -21M in controls

OR (95% CI)

P value

P value

(adjusted)

PsC vs. Control

0.276

0.309

0.82 (0.70, 0.96)

0.042

0.015

PsA vs. Control

0.326

0.309

1.13 (0.99, 1.29)

0.203

0.069

PsA vs. PsC

0.326

0.276

1.40 (1.20, 1.63)

0.002

2.268e-05


Disclosure: V. Chandran, AbbVie Inc., 2,AbbVie Inc., amgen, celgene, eli lilly, Janssen, Novartis, Pfizer and UCB, 5,Eli Lilly and Co., 9; Q. Li, None; R. Machhar, None; F. Abji, None; J. Y. Ye, None; R. Nair, None; P. Stuart, None; K. Oikonomopoulou, None; J. T. Elder, None; D. D. Gladman, Amgen, AbbVie, Celgene, Eli Lilly, Janssen, Novartis, Pfizer and UCB, 2,Amgen, AbbVie, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer and UCB, 5; P. Rahman, AbbVie, Amgen, BMS, Celgene, Eli-Lilly, Janssen, Pfizer, Novartis, Merck, UCB, 5,Janssen, 2,AbbVie, Amgen, BMS, Celgene, Eli-Lilly, Janssen, Pfizer, Novartis, Merck, UCB, 8.

To cite this abstract in AMA style:

Chandran V, Li Q, Machhar R, Abji F, Ye JY, Nair R, Stuart P, Oikonomopoulou K, Elder JT, Gladman DD, Rahman P. −21 HLA-Class I Dimorphism Differentiates Psoriatic Arthritis (PsA) from Psoriasis without Psoriatic Arthritis (PsC) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/%e2%88%9221-hla-class-i-dimorphism-differentiates-psoriatic-arthritis-psa-from-psoriasis-without-psoriatic-arthritis-psc/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/%e2%88%9221-hla-class-i-dimorphism-differentiates-psoriatic-arthritis-psa-from-psoriasis-without-psoriatic-arthritis-psc/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology